Breast cancer+2
RecruitingA Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer
- Disease:Breast cancerBreast cancer metastatic+1
- Substances:CapivasertibFulvestrant+1
Luxembourg- Participants:18–64 years · 65+ years
- Substances:Capivasertib
